Dr. Udayan Guha, MD. PhD is an esteemed physician scientist with more than 15 years of clinical development experience between academia, government, pharma, and biotech in targeted therapy, immunotherapy/immunomodulatory therapy, and cellular therapy. He currently serves as the Senior Vice President, Clinical and Translational Development at NextCure Inc., Beltsville, MD. In this role Dr. Guha oversees clinical development across the NextCure portfolio that includes three current Phase1/2 studies and three assets that are undergoing IND-enabling studies. Dr. Guha regularly participates in all Board Meetings and is a part of Executive team of NextCure Inc. Prior to his current role at NextCure Inc., he was the Vice President and Head of Clinical Development at TCR2 Therapeutics in Cambridge, MA. Before joining TCR2, he held Senior Director and Director positions at Bristol-Myers Squibb in Early Clinical Development where he contributed to several first-in-class and first-iin-human assets.

His tenure at the National Cancer Institute (NCI) saw him serving as an Investigator and Head of Cancer Signaling Networks Section in the Thoracic and GI Malignancies Branch, NCI, NIH. During this time, he led various investigator-initiated clinical studies, focusing on innovative treatments for lung cancer and other thoracic malignancies. He was also the principal investigator running a laboratory studying tumor heterogeneity, mechanisms of resistance to targeted therapy using proteogenomics and mass spectrometry-based quantitative proteomics.

Guha’s academic achievements are complemented by his extensive involvement in professional organizations such as the American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Society of Immunotherapy of Cancer (SITC), International Association for the Study of Lung Cancer (IASLC), Human Proteome Organization (HUPO), and American Society for Mass Spectrometry (ASMS).

Throughout his career, Dr. Guha has received numerous awards and honors, including research grants and recognition for his contributions to the field of oncology. He has also been invited to speak at prestigious conferences and institutions worldwide, sharing his expertise in cancer research and clinical development.

As a board-certified oncologist with a strong research background, Dr. Guha continues to make significant contributions to the field of medical science, driven by his passion for advancing cancer treatment and improving patient outcomes.

Udayan Guha, is an esteemed professional with a rich background in medical research and clinical development. He obtained his Ph.D. in Neuroscience from the Albert Einstein College of Medicine, Bronx, NY in 2003 and his M.B.B.S. from the All India Institute of Medical Sciences, N. Delhi, India in 1995.

Character: Udayan Guha, demonstrates integrity and professionalism in all his endeavors, earning the trust and respect of colleagues and collaborators alike.

Knowledge: With a diverse academic background and extensive experience in medical research and clinical development, Dr. Guha possesses a deep understanding of oncology and neuroscience, enabling him to make significant contributions to the field.

Strategic: Dr. Guha exhibits strategic acumen in his roles, leveraging his expertise to develop innovative clinical development strategies and advance novel treatments for cancer and other diseases.

Communication: Through effective communication skills, Dr. Guha engages with stakeholders, presents research findings, and collaborates with multidisciplinary teams, facilitating the exchange of ideas and driving progress in medical science.